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SWei Sunny Hann1*, Qing Tang1, Fang Zheng1, Shunyu Zhao1, Jianping Chen2 and ZhiYu Wang2Abstract
Background: Peroxisome proliferator-activated receptors gamma (PPARγ) ligands have been shown to inhibit the
growth of non-small cell lung cancer (NSCLC) cells. However, the mechanisms underlying this effect remain
incompletely elucidated.
Methods: Cell proliferation and apoptosis were measured by cell viability, MTT and caspase3/7 activity assays.
Phosphorylation/protein expression and gene silence/overexpression of AMPKα, phosphoinositide-dependent protein
kinase 1 (PDK1), Egr-1 and PPARγ were performed by Western blot and siRNA/transfection assays. Dual-Luciferase
Reporter Kit was used to measure the PPAR response elements (PPRE) reporter and PDK1 promoter activities, and
ChIP assay was used to detect the Egr-1 protein binding to the DNA site in the PDK1 gene promoter.
Results: We found that ciglitazone, one synthetic PPARγ ligand, inhibited growth and induced apoptosis of NSCLC
cells through decreased expression of PDK1, which was not blocked by GW9662 (a specific PPARγ antagonist).
Overexpression of PDK1 overcame the effect of ciglitazone on cell growth and caspase 3/7 activity. Ciglitazone
increased the phosphorylation of AMPKα and c-Jun N-terminal kinase (JNK), and the inhibitor of AMPK (compound
C), but not JNK (SP600125), reversed the effect of ciglitazone on PDK1 protein expression. Ciglitazone reduced
PDK1 gene promoter activity, which was not observed in cells exposed to compound C, but not silenced of PPARγ
siRNA. Combination of ciglitazone and metformin further reduced PDK1 expression and promoter activity. Furthermore,
we showed that ciglitazone induced the protein expression of Egr-1, which was not observed in cells silencing of
AMPKα. Moreover, silencing of Egr-1 abrogated the effect of ciglitazone on PDK1 promoter activity and cell growth. On
the contrary, overexpression of Egr-1 enhanced the effect of ciglitazone on PDK1 gene promoter activity. ChIP assays
demonstrated that ciglitazone induced Egr-1 protein bind to the specific DNA site in the PDK1 gene promoter.
Conclusion: Collectively, our results demonstrate that ciglitazone inhibits PDK1 expression through AMPKα-mediated
induction of Egr-1 and Egr-1 binding to the specific DNA site in the PDK1 gene promoter, which is independent of
PPARγ. Activation of AMPKα by metformin enhances the effect of ciglitazone. In turn, this leads to inhibition of
NSCLC cell proliferation.
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Lung cancer remains the leading cause of cancer-related
mortality in the United States, and 30% to 40% of newly
diagnosed patients with non-small cell lung cancer
(NSCLC) present with regionally advanced and unre-
sectable stage III disease [1]. Despite recent advances in
understanding the molecular biology of lung cancer
and the introduction of multiple new chemotherapeutic
agents for its treatment, the poor outcomes related to
lung cancer have not changed substantially [2,3]. This
justifies the continuing search for agents with therapeutic
potential against NSCLC.
Peroxisome proliferator-activated receptors (PPARs iso-
types α, β/δ,γ) are ligand-inducible nuclear transcription
factors that heterodimerize with retinoid X receptors and
bind to PPAR response elements (PPRE) located in the
promoter region of PPAR target genes [4]. The role of
PPARγ, one PPAR isotype, has been extensively studied
thanks to the availability of synthetic PPARγ agonists
including antidiabetic drugs, such as rosiglitazone, ciglita-
zone, and pioglitazone [5]. These drugs are also effective in
regulating cell activation, differentiation, proliferation, and
apoptosis through both PPARγ-dependent and -independ-
ent signaling [6,7]. However, the detailed mechanisms re-
sponsible for these effects remain incompletely elucidated.
Stress-activated protein kinase/c-Jun N-terminal kinase
(SAPK/JNK) is a mitogen-activated protein kinase family
member that is activated by diverse stimuli and plays a
critical role in regulating cell fate, being implicated in a
multitude of diseases ranging from cancer to neurological,
immunological and inflammatory conditions. JNK signal-
ing is required for normal mammary gland development
and has a suppressive role in mammary tumorigenesis [8].
AMP-activated protein kinase (AMPK), a heterotrimeric
protein complex with serine/threonine kinase activity, has
been involved in the regulation of a number of physio-
logical processes including β-oxidation of fatty acids, lipo-
genesis, protein and cholesterol synthesis, as well as cell
cycle inhibition and apoptosis. AMPK has been shown to
act upstream and downstream of known tumor suppres-
sors. However, whether AMPK acts as a bona fide tumor
suppressor or a oncogene and, of particular importance, if
AMPK should be targeted for activation or inhibition
during cancer therapy, is controversial [9]. Early growth
response-1 (Egr-1) is a Cys2-His2-type zinc-finger tran-
scription factor. A broad range of extracellular stimuli is
capable of activating Egr-1, thus mediating growth,
proliferation, differentiation or apoptosis. Egr-1 is, there-
fore, participating in the progression of a variety of
diseases such as atherosclerosis or cancer. A growing
body of evidence suggests that Egr-1 functions as a tumor
suppressor [10-12].
In an effort to explore the anti-tumor effects of cigli-
tazone on potential targets, we turned our attention to3-phosphoinositide-dependent protein kinase 1 (PDK1), a
master regulator of signal cascades that is involved in
suppression of apoptosis and promotion of tumor growth
including lung cancer [13]. Reduction of PDK1 by small
interfering RNA (siRNA) in several cancer cells results in
significant growth inhibition [14-17]. These observations
suggest that PDK1 can be used as a target for cancer
therapies.
Here, we report that ciglitazone inhibits NSCLC prolif-
eration by inhibiting PDK1 expression through activation
of AMPKα and induction of Egr-1 that is independent of
PPARγ.
Results
Ciglitazone decreased growth and induced apoptosis in
lung cancer cells, and inhibited PDK1 protein expression
independent of PPARγ
We first examined the effect of ciglitazone on growth
and apoptosis of lung cancer cells. We found that ciglita-
zone inhibited growth of lung cancer cell H1650 in the
time- and dose-dependent manner, with significant inhib-
ition observed at 20 μM at 48 h (Figure 1A, upper panel).
Similar results were also observed in other NSCLC cell
lines (Figure 1A, lower panel). We also showed that cigli-
tazone induced caspase 3/7 activity in H1650 cells indicat-
ing increase in apoptosis (Figure 1B). We then examined
whether ciglitazone affected the expression of PDK1. We
found that ciglitazone inhibited PDK1 protein expression
in a time- and dose-dependent manner, with an effective
response of 20 μM at 24 h in H1650 cells (Figure 1C).
Reduction of PDK1 protein expression by ciglitazone
was also found in other NSCLC cell lines (Figure 1D).
We then tested whether the effects of ciglitazone on
PDK1 were mediated through the activation of PPARγ.
We showed that, while ciglitazone increased the PPRE
luciferase activity (activation of PPAR) (Figure 2A), the
effects of ciglitazone on PDK1 expression were not
eliminated in the presence of GW9662, a specific PPARγ
antagonist (Figure 2B) and in cells (H1299 and H1650)
silencing of PPARγ (not shown). The result suggests that
PPARγ-independent signals mediate the effect of ciglita-
zone on PDK1 protein expression.
Next, to test whether ciglitazone affects cell growth
through PDK1-mediated signals, we blocked the PDK1
gene using PDK1 siRNA. We showed that knockdown of
PDK1 significantly reduced PDK1 production, while the
control siRNA had no effect (Figure 2C, upper panel).
Cells exposed to PDK1 siRNA showed a slight reduction
in cell proliferation at baseline; however, they showed
significant reduction in growth in the presence of ciglita-
zone as determined by cell viability assay (Figure 2C,
lower panel). Overexpression of PDK1 has been reported
to correlate with tumor progression [15]. We found that
overexpression of PDK1 abrogated the effect of ciglitazone
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Figure 1 Ciglitazone decreased growth and induced apoptosis in lung cancer cells. A, H1299 cells were treated with increased concentrations
of ciglitazone for up to 72 h (upper panel). NSCLC cells indicated were treated with ciglitazone (20 μM) or up to 48 h (lower panel). The cell viability
was determined using the MTT assay as described in the Materials and Methods section in three separate experiments. B, Caspase 3/7 activity assay
was performed on H1299 cells treated with or without ciglitazone for 48 h. Relative caspase 3/7 activity is indicated as percentage of untreated control
cells. Results represent those obtained in three experiments. *indicates significant difference as compared to the untreated control group (P < 0.05).
C, Cellular protein was isolated from H1299 cells that were cultured with increased concentrations of ciglitazone for up to 24 h (upper), or with
ciglitazone (20 μM) for indicated period of time (lower), followed by Western blot. D, Cellular protein were isolated from NSCLC cells (H1299, PC9,
A549, H1957, H358 and H1650) that were cultured with ciglitazone (20 μM) for up to 24, followed by Western Blot.
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http://www.molecular-cancer.com/content/13/1/149on cell growth (Figure 2D, lower panel) and caspase 3/7
activity (Figure 2E). Transfection with PDK1 expression
vector was confirmed by Western blot (Figure 2D-E,
upper panel). Together, this suggested that ciglitazone
not only inhibited growth but also increased apoptosis
of lung cancer cells through, at least in part, the inhibition
of PDK1.
The role of AMPKα and SAPK/JNK in mediating the effect
of ciglitazone on PDK1 protein expression
Studies by this group and others also demonstrated a
role for AMPK in mediating the effect of PPARγ ligands,
such as thiazolinediones (TZDs) compounds, in differentcell systems [18,19]. We showed that ciglitazone increased
phosphorylation of AMPKα and SAPK/JNK with maximal
effect observed at 2–4 h in H1650 cells (Figure 3A-B).
Interestingly, the inhibitors of AMPK, compound C, but
not of SAPK/JNK, SP600125, blocked the inhibitory ef-
fect of ciglitazone on PDK1 protein expression in both
H1650 and H1299 cells (Figure 3C). Similarly, silencing
of AMPKα abrogated the effect of ciglitazone on PDK1
protein (Figure 3D). This indicates the specificity of
AMPKα activation in this process. Interestingly, com-
bination treatment of ciglitazone and metformin, an ac-
tivator of AMPK, further reduced the PDK1 protein
expression (Figure 3E).
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Figure 2 (See legend on next page.)
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Figure 2 Ciglitazone inhibited PDK1 protein expression independent of PPARγ. A, H1299 and H1650 cells were transfected with control or
PPRE X3-TK-luc reporter (from Addgene) for 24 h, followed by treating with ciglitazone for an additional 24 h. Afterwards, the Luciferase reporter
activity was measured using Luciferase Assay System (Promega) according to manufacturer's instructions. The bars represent the mean ± SD of at
least three independent experiments for each condition. *indicates significant difference as compared to the untreated control group (P < 0.05).
B, Cellular protein was isolated from H1299 and H1650 cells cultured for 1 h in the presence or absence of GW9662 (20 μM) before exposing the
cells to ciglitazone (20 μM) for an additional 24 h, then subjected to Western blot analysis. C, H1299 cells were transfected with control or PDK1
siRNA (80 nM) for 40 h, followed by exposing the cells to ciglitazone (20 μM) for an additional 24 h. Afterwards, the luminescence of viable cells
was detected using Cell Titer-Glo Luminescent Cell Viability Assay kit. D-E, H1299 cells were transfected with the control and PDK1 expression
vectors using the oligofectamine reagent according to the manufacturer’s instructions. After 24 h of incubation, cells were treated with or without
ciglitazone for an additional 24 h. Afterwards, the luminescence of viable cells was detected using Cell Titer-Glo Luminescent Cell Viability Assay
kit (D). In separate experiment, the relative caspase 3/7 activity (E) is indicated as percentage of untreated control cells. The bars represent the
mean ± SD of at least four independent experiments for each condition. Insert on the top panel shows a Western blot for PDK1 protein. *indicates
significant difference as compared to the untreated control group (P < 0.05). **Indicates significance of combination treatment as compared with
ciglitazone alone (P < 0.05).
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independent of PPARγ activation
We also examined if the effects of ciglitazone on PDK1
expression occurred at the transcriptional level. As shown
in Figure 4A, the PDK1 gene promoter contains multiple
transcription factor binding sites including PPRE, Egr-1,
nuclear factor-κB (NF-κB) and p53, among others. We
found that NSCLC cells transfected with wild-type PDK1
promoter-luciferase reporter construct showed decreased
activity when exposed to ciglitazone (Figure 4B). As
expected, metformin enhanced the inhibitory effect of
ciglitazone (Figure 4B).
Next, we assessed whether PPARγ activation played a
role in mediating the effect of ciglitazone on PDK1 pro-
moter activity. The effect of ciglitazone on inhibition of
PDK1 promoter activity was not abrogated by PPARγ
siRNA (Figure 4C, lower panel). Note that PPARγ siRNA
blocked PPARγ protein expression (Figure 4C, upper
panel). As expected, we found that compound C re-
duced the effect of ciglitazone on PDK1 promoter activity
(Figure 4D).
The role of transcription factor Egr-1 in mediating the
effect of ciglitazone on expression of PDK1 and cell growth
We further tested the role of the transcription factors in
mediating the effect of ciglitazone on PDK1 expression
in human lung carcinoma cells. We showed that ciglita-
zone significantly induced the expression of Egr-1 protein
in a time–dependent manner, while it had little effect on
p65 and p53 (Figure 5A, upper panel). Note that a synergy
was observed in the combination of ciglitazone and met-
formin treatment (Figure 5A lower panel). Interestingly,
we also found that silencing of AMPKα abolished the
effect of ciglitazone on Egr-1 protein expression, further
suggesting the critical role of AMPKα activation in this
process (Figure 5B). Next, we found that while cells
transfected with Egr-1 siRNA slightly increased PDK1
promoter activity at baseline, it greatly antagonized the
inhibitory effect of ciglitazone on PDK1 promoter activity.Note that the control siRNA had no effect (Figure 5C,
lower panel). Egr-1 siRNA reduced the production of
Egr-1 protein (Figure 5C, upper panel). Furthermore, it
eliminated the ciglitazone-reduced PDK1 protein expres-
sion, whereas the control siRNA had no effect (Figure 5D).
Consistent with these findings, we found that cells trans-
fected with Egr-1 siRNA blocked the inhibitory effects of
ciglitazone on cell growth (Figure 5E). The control siRNA
had no effect.
However, cells co-transfected with an Egr-1 expression
vector showed little or no synergistic effect on PDK1
promoter activity (Figure 6A), suggesting the specificity
of Egr-1. Next, by ChIP assays, we showed that ciglitazone
induced Egr-1 protein binding to the Egr-1 DNA site in
the PDK1 gene promoter (Figure 6B).
Discussion
The expression of PPARγ and the effects of PPARγ ligands
on cell growth have been extensively studied in many
carcinoma cell types including lung [6,20]. However,
the exact mechanisms mediating the effects of PPARγ
ligands on cell growth inhibition are not fully understood.
We have found that ciglitazone, a TZD and one of the
synthetic PPARγ ligands, inhibited growth and induced
apoptosis of NSCLC cells through reduction of PDK1, a
kinase and master regulator of a number of downstream
signal cascades that are involved in suppression of
apoptosis and promotion of tumor growth including
lung cancer [13,21]. Inhibition of PDK1 in several cancer
cells results in significant cell growth inhibition [14-17].
These observations suggest that PDK1 can be considered
as a key mediator of neoplasia and a promising anticancer
target. This result, together with the finding that ex-
ogenous PDK1 diminishes the effect of ciglitazone on
cancer cell growth, suggests a critical role of PDK1 in
this process.
The concentrations of ciglitazone used here, found
significantly inhibition of PDK1 gene expression and cell
growth , are consistent or even lower with those reported
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Figure 3 The role of AMPK and SAPK/JNK in mediating the effect of ciglitazone on PDK1 protein expression. A-B, Cellular protein were
isolated from H1299 cells that were cultured with ciglitazone for up to 24, followed by Western Blot for phosphor-AMPKα, SAPK/JNK and total
AMPKα, SAPK/JNK. C, Cellular protein was isolated from H1299 and H1650 cells treated with SP600125 (10 μM) or compound C (20 μM) for 1 h
before exposure of the cells to ciglitazone for an additional 24 h. Afterwards, Western blot was performed. D, Cellular protein was isolated from
H1299 cells transfected with control or AMPKα siRNA (80 nM) for 40 h, followed by exposing the cells to ciglitazone for an additional 24 h.
Afterwards, Western blot was performed. E, Cellular protein was isolated from H1299 cells treated with ciglitazone and metformin (5 mM) for
24 h, followed by Western Blot. GAPDH served as internal controls for normalization purposes. The bar graph represents the mean ± SD of
PDK1/GAPDH of at least three independent experiments. *Indicates significant difference from untreated control. **Indicates significance of
combination treatment as compared with ciglitazone alone (P < 0.05).
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http://www.molecular-cancer.com/content/13/1/149by others which showed a significant effect on cell growth
and apoptosis at clinically achievable concentrations
[22-25]. For example, ciglitazone inhibited the growth
of androgen-dependent and -independent human prostate
cancer cells starting at 10 and reached maximal at even
45 μM concentrations [23]. In another study, ciglitazone
showed to significantly inhibit cell viability and prolifera-
tion of brain tumor stem cells starting at 5 and continued
to 25 μM concentration [25].We demonstrated that ciglitazone inhibited the ex-
pression of PDK1 protein independent of PPARγ sig-
nals. Consistent with this, the PPARγ-independent
signals mediating the effects of PPARγ ligands on gene
expression and cell proliferation including lung cancer
have been shown in other studies [24,26,27] although
PPARγ-dependent signals were observed [28,29]. We
reasoned that targeting PDK1 may also involve such
mechanisms by which ciglitazone inhibits NSCLC cell
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Figure 4 Ciglitazone decreased PDK1 promoter activity. A, The human PDK1 wild type reporter construct schematics are presented. These
regions contain several transcription factor binding sites including PPRE, Egr-1, p53 and NF-κB. B, H1299 and H1650 lung cancer cells (1 × 105 cells)
were transfected with a wild type human PDK1 promoter reporter construct ligated to luciferase reporter gene and an internal control Renilla
Luciferase Reporter Vector for 24 h. Afterward, cells were treated with ciglitazone for an additional 24 h. C, H1299 cells were transfected with
control or PPARγ siRNAs (80 nM) together with a wild type ILK promoter construct for 30 h, then cells were exposed to ciglitazone for an
additional 24 h. Insert on the top shows Western blot result for PPARγ protein. GAPDH served as internal control for normalization purposes.
D, H1299 cells (1 × 105 cells) were transfected with a wild type human PDK1 promoter reporter construct ligated to luciferase reporter gene
and an internal control Renilla Luciferase Reporter Vector as described in Materials and Methods for 24 h. Afterwards, cells were treated with
SP600125 (10 μM) for 1 h before exposure of the cells to ciglitazone for an additional 24 h. The ratio of firefly luciferase to renilla luciferase activity was
quantified as described in Material and Methods. The bars represent the mean ± SD of at least four independent experiments for each condition. *Indicates
significant increase of activity as compared to controls. **Indicates significance of combination treatment as compared with ciglitazone alone (P < 0.05).
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http://www.molecular-cancer.com/content/13/1/149growth. Given the fact that silencing of the PPARγ
gene by siRNA had no effect on blockage of the effect
of ciglitazone on PDK1 promoter activity, additionalexperiments are required to explore the contribu-
tions of PPARγ-independent mechanisms in these
processes.
Co
n
Cig
Co
n s
iR
NA
Eg
r-1
 
siR
NA
Cig
+E
gr-
1 s
iR
NA
Cig
+C
on
 si
RN
A0.0
0.5
1.0
**
* *
E
Lu
m
in
es
ce
n
ce
 
(R
LU
)
x
10
00
00
PDK1
D
Egr-1
GAPDH
Con siRNA
Egr-1 siRNA
Cig
− − − + − +
− − + − + −
− + − − + +
Co
n
Cig
Eg
r-1
 
siR
NA
Co
n s
iR
NA
Cig
+E
gr-
1 s
iR
NA
Cig
+C
on
 si
RN
A0.0
0.5
1.0
1.5
**
*
*
PD
K
1
/G
AP
D
H
pr
ot
ei
ns
 
(o
pt
ica
l d
en
sit
y)
Egr-1
Cig, 20 µM
0    2     4     8    24   48    h   
A p65
p53
GAPDH
Cig
Metformin
− + − +
− − + +
Egr-1
GAPDH
B
GAPDH
Egr-1
AMPKα
Con siRNA
AMPKα siRNA
Cig
− − − + − +
− − + − + −
− + − − + +
E
gr
-1
/G
A
P
D
H
pr
ot
ei
n
s
 
(o
pt
ic
al
 d
en
si
ty
)
Co
n
Ci
g
Eg
r-
1 
siR
NA
Co
n 
siR
NA
ANRis
1
-rgE+giC C
ig
+C
on
 s
iR
NA
0.0
0.5
1.0
1.5
**
* *
p-AMPKα
AMPKα
R
el
at
iv
e
 
P
D
K
1
lu
ci
fe
ra
se
a
c
ti
v
ity
 
 
 
 
 
 
 
 
 
 
C Egr-1
GAPDH
Co
n
Co
n s
iRN
A
Egr
-
1 s
iRN
A
Co
n
Ci
g
Co
n 
siR
NA
Eg
r-1
 si
RN
A
Ci
g+
Co
n s
iR
NA
Ci
g+
Eg
r-1
 si
RN
A
0
5
10
15
**
*
*
Figure 5 (See legend on next page.)
Hann et al. Molecular Cancer 2014, 13:149 Page 8 of 13
http://www.molecular-cancer.com/content/13/1/149
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Figure 5 Ciglitazone induces Egr-1 protein expression; silencing of Egr-1 abrogates the effect of ciglitazone on PDK1 promoter activity,
protein expression and cell proliferation. A, Cellular proteins were isolated from H1299 cells treated with ciglitazone (20 μM) for the indicated
time period (upper panel) or with metformin (5 mM) for 24 h (lower panel). Afterwards, Western blot analyses were performed for detecting
Egr-1, p65 and p53 proteins. B, H1299 cells were transfected with control or AMPKα siRNA (80 nM) for 30 h before exposing the cells to ciglitazone
(20 μM) for an additional 24 h followed by Western blot. C, H1299 cells were transfected with control or Egr-1 siRNA (80 nM) together with a wild type
PDK1 promoter construct for 30 h, then cells were exposed to ciglitazone (20 μM) for an additional 24 h. Insert shows the Western blot result for Egr-1
protein. D, H1299 cells were transfected with control or Egr-1 siRNA (80 nM) for 30 h before exposing the cells to ciglitazone (20 μM) for an additional
24 h, followed by Western blot. E, H1299 cells were transfected with control or Egr-1 siRNA (80 nM) for 30 h before exposure of the cells to ciglitazone
(20 μM) for an additional 24 h. Afterwards, the luminescence of viable cells was detected using Cell Titer-Glo Luminescent Cell Viability Assay kit. The
bars represent the mean ± SD of at least four independent experiments for each condition. *Indicates significant difference as compared to the control.
**Indicates significance of combination treatment as compared with ciglitazone alone (P < 0.05).
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http://www.molecular-cancer.com/content/13/1/149Interestingly, PDK1 knockdown alone did not affect
cell proliferation significantly. However, inhibition of
PDK1 in the setting of ciglitazone treatment resulted in
largely growth inhibition. This suggests that other factors
are important for control of NSCLC cell proliferation. It
also suggests that the growth inhibitory effects of cigli-
tazone may occur by concomitant actions on pathways
other then PDK1. Report shown that ciglitazone exerts
effects on several other targets that were implicated in
control of lung cancer growth [30,31].
In this study, we showed that activation of AMPKα
played a vital role in mediating the effect of ciglitazone
on PDK1 expression. In addition, activation of AMPK
enhanced the effect of ciglitazone on PDK1 expression
and promoter activity. Data demonstrated that synthetic
PPARγ ligands regulated several kinase signaling pathways
including AMPK in different cells [32,33]. Activation or
inactivation of AMPK has been shown to link synthetic
PPARγ agonists-mediated signaling to the transcriptional
regulation of genes that are crucial for cell growth inhib-
ition [32,34]. Considering the recent data for the dual role
of AMPK [9], we believed that more dedicated studies are
required to further elucidate the biological function and
relevant signaling of this kinase.
Having demonstrated the important role of PDK1, we
further investigated whether the ciglitazone–mediated
downregulation of PDK1 reflected inhibition of trans-
activation of the PDK1 gene. Our results suggested that
increased Egr-1 protein expression and binding to the
upstream areas of PDK1 gene promoter played an im-
portant role in mediating the effect of ciglitazone.
Knockdown of Egr-1 abrogated the effect of ciglitazone
on PDK1 expression and on cell proliferation, whereas
overexpression of Egr-1 had no further effect of ciglita-
zone on PDK1 promoter activity confirming the inhibitory
property of this transcription factor. It also suggested the
specificity of Egr-1 played in this process. To our know-
ledge, the role of Egr-1 in regulation of PDK1 expression
has never been reported. Egr-1 functions as a tumor sup-
pressor in many cancers [10-12]. Loss of Egr-1 expression
has been associated with invasion and anti-apoptotic
events, whereas overexpression of Egr-1 suppressed thetumorigenicity and metastatic potential in several cancer
cells including lung [34,35]. However, opposite role of
Egr-1 were also found in several studies [36,37]. Thus
Egr-1 is considered to play dual roles depending on the
cell types and environment. One study showed that sev-
eral PPARγ ligands including TZD induced the expres-
sion of Egr-1 through PPARγ-independent pathway in
breast cancer cells [38]. Thus, other factors responsible
for this effect (in addition to Egr-1) need further explor-
ation. ChIP assays showed that Egr-1 protein occupancy
of the Egr-1 sites in the upstream areas of PDK1 gene
promoter was enhanced by exposure of cells to ciglita-
zone. Further studies are required by site-directed muta-
genesis experiments to confirm this. Moreover, the detail
mechanisms responsible for the effect of metformin in this
process needs to be determined.
Conclusion
Our results demonstrate that ciglitazone inhibits PDK1
expression through AMPKα-mediated induction of Egr-1
protein expression and Egr-1 binding to specific DNA
sequences in the PDK1 gene promoter, which is inde-
pendent of PPARγ activation. Activation of AMPKα by
metformin enhances the effect of ciglitazone on Egr-1
and PDK1 protein expression. In turn, this leads to in-
hibition of NSCLC cell proliferation (Figure 6C). This
study provides a novel mechanism by which the antidi-
abetic drug inhibits human lung cancer cell growth,
and targeting the PDK1 may be a potential therapeutic
strategy for inhibition of lung cancer growth.
Materials and methods
Culture and chemicals
The human NSCLC cell lines A549, H1650, PC9, H1975,
H1299 and H358 were obtained from the Cell Line Bank at
the Laboratory Animal Center of Sun Yat-sen University
starting March 2012 (Guangzhou, China) and grown in
RPMI-1640 medium supplemented with 10% heat-
inactivated FBS, HEPES buffer, 50 IU/mL penicillin/
streptomycin, and 1 μg amphotericin (complete medium).
All cell lines have been tested and authenticated for absence
of Mycoplasma, genotypes, drug response, and morphology
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Figure 6 Overexpression of Egr-1 reduces PDK1 promoter activity. A, H1299 cells (1x105 cells) were transfected with control and Egr-1 expression
reporter constructs, and together with a wild type PDK1 promoter construct and an internal control Renilla Luciferase Reporter Vector as described in
Material and Methods section for 24 h, then treated with ciglitazone (20 μM) for an additional 24 h. The insert in upper panel represents Western blot
results for Egr-1 protein. B, H1299 cells were lysed after exposure of ciglitazone (20 μM) for 24 h, and nuclei were isolated and then sonicated. Chromatin
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China) in the Laboratory and Animal Center at Sun
Yat-sen University in April 2010 and August 2012. Poly-
clonal antibodies specific for PDK1, phosphor-AMPKα
(thr172) phosphor-p-SAPK/JNK (Thr183/Tyr185) and total
AMPKα and SAPK/JNK were purchased from Cell Signal-
ing (Beverly, MA). Polyclonal antibodies against PPARγ,
AMPKα, p53, p65 and Egr-1 were purchased from SantaCruz Biotechnology, Inc (Santa Cruz, CA, USA). Ciglita-
zone, SP600125, GW9662, compound C, metformin and
other chemicals were purchased from Sigma Aldrich (St.
Louis, MO, USA) unless otherwise indicated.
Western blot analysis
Protein concentrations were determined by the Bio-Rad
protein assay. Equal amounts of protein from whole cell
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separated on 10% SDS polyacrylamide gels. Membranes
were incubated with antibodies against PDK1, PPARg
phosphor-AMPKα (thr172) phosphor-p-SAPK/JNK
(Thr183/Tyr185) and total AMPKα and SAPK/JNK,
p53, p65 and Egr-1. The membranes were washed and in-
cubated with incubation with a secondary goat antibody
raised against rabbit IgG conjugated to horseradish
peroxidase (Cell Signaling, Beverly, MA, USA). The
membranes were washed again and transferred to
freshly made ECL solution (Pierce, Rockford, IL, USA)
for 1 min, and exposed to X-ray film.MTT cell viability assay
Cell viability was measured using the 3-(4, 5-dimethyl-
thiazol-2- yl)-2, 5-diphenyltetrazolium bromide (MTT)
assay. Briefly, NSCLC cells (5 × 103 cells/well) were
counted and seeded into a 96-well microtiterplate. The
cells were treated with increasing concentrations of
ciglitazone for up to 72 h. After incubation, 10 μL MTT
solution (5 g/L) was added to each well and incubated at
37°C for an additional 4 h. Supernatant was removed, then
150 μL DMSO was added to each well and oscillated for
10 min. Absorbance at 490 nm was determined through
the use of ELISA reader (Perkin Elmer, Victor X5, USA).
Each experiment was repeated at least three times. Cell
viability (%) was calculated as (absorbance of test sample/
absorbance of control) × 100%.CellTiter-Glo luminescent cell viability assay
Human lung carcinoma cells were treated with com-
pound C for 2 h or were transfected with control or
Egr-1 siRNA or PDK1 expression vectors for 24 h
before exposure of the cells to ciglitazone for an add-
itional 24 h in 96-well plates in DMEM media with
0.5% FBS. Afterwards, cell viability was measured using
the CellTiter-Glo Luminescent Cell Viability Assay kit
(Promega, Shanghai, China) according to the instructions
of the manufacturer.Detection of caspase-3/7 activity
Enzymatic activity of caspase-3/7 was measured using
the Caspase-Glo 3/7 Assay kit (Promega, Shanghai, China)
according to the manufacturer’s instruction. Briefly, NSCLC
cells were seeded in 96-well plates and treated with or
without 20 μM of ciglitazone for 48 h. Afterwards, the
cells were lysed and incubated with 100 μL of Apo-ONE
Caspase-3/7 reagent (substrate and buffer in the ratio of
1:100). After 1 h incubation in the dark at RT, the fluor-
escence of each well was measured at 485–520 nm by
reading in an Epoch microplate reader (Biotek Instruments;
Winooski, VT, USA).Treatment with AMPKα, PDK1, Egr-1 and PPARγ small
interfering RNA (siRNA)
The siRNA human PDPK1 (EHU071261) was ordered
from Sigma (Shanghai, China). The AMPKα (Cat No.
sc-45312), Egr-1 siRNA (Cat No. sc-105070), PPARγ
siRNA (Cat No. sc-29455), and control nonspecific siRNA
oligonucleotides (Cat No. sc-37007) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). For the
transfection procedure, cells were grown to 60% conflu-
ence, and PDK1, Egr-1, and PPARγ and control siRNAs
were transfected using the oligofectamine reagent (Invi-
trogen, Shanghai, China) according to the manufacturer’s
instructions. Briefly, Lipofectamine was incubated with
serum–free medium for 10 min., mixed with siRNA (80
nM), incubated for 20 min at room temperature before
the mixture was diluted with medium and added to cells.
After culturing for 30 h, cells were washed, resuspended
in new culture media in the presence or absence of ciglita-
zone for an additional 24 h for Western Blot, cell growth,
luciferase report assays and other experiments.
Transient transfection assays
The original human PDK1 promoter construct was a gift
from Dr. Michalik at the University of Lausanne and
have been reported previously [39]. The PDK1 promoter
construct contains approximately 1500 base pairs of the
5’ flanking region of the human PDK1 gene connected
to the pGL3 basic luciferase reporter vector [39]. Briefly,
NSCLC cells were seeded at a density of 5 × 105 cells/well
in 6-well dishes and grown to 50 –60% confluence. For
each well, 2 μg of the control or PPRE X3-TK-luc reporter
(Addgene, plasmid 1015) [40], above PDK1 plasmid
DNA constructs, or overexpression of PDK1 (pDONR223-
PDPK1) (Addgene plasmid 23801) [41] or Egr-1 expression
vectors [obtained from Dr. Thomas Eling (NIEHS, USA)
and have been reported previously] [42], with or without
0.2 μg of the internal control phRL-TK Renilla Luciferase
Reporter Vector were co-transfected into the cells with the
oligofectamine reagent (Invitrogen, Shanghai, China). In
parallel experiments, NSCLC cells transfected with Egr-1,
PPARγ, or control siRNAs (80 nM each) for 30 h followed
by exposed the cells to ciglitazone for an additional 24 h.
The preparation of cell extracts and measurement of lucif-
erase activities were determined using the Dual-Luciferase
Reporter Kit (Promega, Shanghai, China). Firefly luciferase
activity was normalized with Renilla luciferase activity
within each sample.
Chromatin immunoprecipitation assay (ChIP)
ChIP assays were performed as described by other study
[43]. Briefly, cells were incubated in 1% formaldehyde
for 10 min at 37°C, quenched with 125 mmol/L glycine,
lysed in SDS buffer with protease inhibitors (Roche),
0.5 mmol/L phenylmethyl-sulfonyl fluoride and sonicated.
Hann et al. Molecular Cancer 2014, 13:149 Page 12 of 13
http://www.molecular-cancer.com/content/13/1/149Fragmented chromatin was pre-cleared by adding salmon
sperm-DNA/protein A-agarose beads. A portion of the
supernatant was kept as “input” material. The remaining
cleared chromatin was incubated overnight with or with-
out 5 μg of anti-Egr-1 antibody or normal human IgG
(Upstate Biotechnology, Shanghai, China). DNA (10 μg)
from each immunoprecipitation was reserved for input
controls. DNA was purified with QIAquick PCR purifi-
cation column (QIAGEN Sciences, MA) and genomic
sequences of interest were amplified by PCR using
primers Egr-1 forward (−4392/-4402) 5′- GAGGGTGG
ACACAGTTGAGTCAG-3′ and reverse ′5-TGGACAA
CATTAGCAAGACCCTG-3′. A total of 2% of each IP
was assayed by PCR using primers specific for the region
of interest (218 bp).Statistical analysis
All experiments were repeated a minimum of three times.
All data were expressed as means ± SD. and then proc-
essed using SPSS10.0 software. Statistical significance was
determined with Student’s t test (two-tailed) comparison
between two groups of data set. Asterisks shown in the
figures indicate significant differences of experimental
groups in comparison with the corresponding control
condition (P < 0.05, see figure legends).
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